A randomized multicenter trial of adjuvant IMF-001 after curative resection for esophageal cancer with NY-ESO-1 antigen (phase II study)

Trial Profile

A randomized multicenter trial of adjuvant IMF-001 after curative resection for esophageal cancer with NY-ESO-1 antigen (phase II study)

Completed
Phase of Trial: Phase II

Latest Information Update: 21 May 2018

At a glance

  • Drugs IMF 001 (Primary)
  • Indications Oesophageal cancer; Squamous cell cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 14 May 2018 Status changed from active, no longer recruiting to completed.
    • 19 Nov 2015 Status changed from recruiting to active, no longer recruiting as reported by University Hospital Medical Information Network - Japan record.
    • 12 May 2015 Planned End Date changed from 1 Mar 2016 to 31 Oct 2017 as reported by University Hospital Medical Information Network - Japan.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top